ETF · BATS · USD
AUM
—
Expense ratio
—
Yield
—
YTD return
—
Last price
—
Thematic Sector · Coverage 13% · low
Today
72.0
Outlook
49.2
Block A (composite-derived)
34.7
Block C (market behavior)
90.4
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
34.7
Coverage 13% · low
Liquidity
—
Expenses
—
Performance
—
Volatility
34.7
Dividend
—
Concentration
—
Smart Money
—
Activist
—
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund from Franklin Templeton Investments in the Mixed asset class. Launched in 2020.
Bullish Whales composite rating: 35 out of 100. Evidence coverage 13% across 1 of 8 axes. Strongest axes: volatility.
Annualized one-year realized volatility 22%, classified high.
etf_composite_score_current · composite_score, confidence, coverage_pct, volatility_scoreetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yNo description available for this ETF yet. Issuer-direct overview text may be added in a future refresh.
Net AUM change history is not yet available for this ETF. Fund-flow time series is a Phase B deliverable.
Current AUM: —. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for HELX are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.